샘플 요청 목록

 카트 문의
시장보고서
상품코드
1534047

세계의 신경아세포종 치료제 시장

Neuroblastoma Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 250 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경아세포종 치료제 세계 시장, 2030년까지 11억 달러에 달할 것으로 전망

2023년 8억 270만 달러로 추정되는 신경아세포종 치료제 세계 시장은 2023-2030년 분석 기간 동안 연평균 5.1% 성장하여 2030년에는 11억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 면역요법은 CAGR 5.7%를 기록하여 분석 기간 종료 시점에 6억 1,680만 달러에 도달할 것으로 예상됩니다. 화학요법 부문의 성장률은 분석 기간 동안 CAGR 4.8%로 추정됩니다.

미국 시장 2억 1,100만 달러로 추정, 중국은 CAGR 5.0%로 성장 전망

미국의 신경아세포종 치료제 시장은 2023년 2억 1,100만 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 시장 규모가 1억 8,310만 달러에 달할 것으로 예상되며, 2023-2030년 분석 기간 동안 5.0%의 CAGR을 기록할 것으로 예측됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 4.9%와 4.3%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 4.0%의 CAGR로 성장할 것으로 예상됩니다.

세계 신경아세포종 치료제 시장 - 주요 동향 및 촉진요인 요약

신경모세포종은 주로 유아가 걸리는 암의 일종으로 신체 여러 부위에서 발견되는 미성숙한 신경세포에서 발생합니다. 신경모세포종의 치료 상황은 수년 동안 크게 발전해 왔으며, 약물 개발의 발전이 치료 성과의 개선에 매우 중요한 역할을 하고 있습니다. 기존의 치료법으로는 수술, 방사선 치료, 화학요법 등이 있지만, 이들 치료법은 종종 큰 부작용을 동반하고 성공률도 다양합니다. 최근에는 암세포의 성장과 증식 능력을 직접적으로 억제하는 것을 목표로 하는 보다 표적화된 치료법으로 전환되고 있습니다. 이러한 표적치료제 중 하나로 지누툭시맙과 같은 단클론항체를 사용하는 것이 있습니다. 지누툭시맙은 신경아세포에서 발견되는 GD2 강글리오사이드(GD2 ganglioside)에 결합하여 면역체계에 의한 파괴의 표식이 됩니다. 그 외 주목할 만한 약물로는 신경아세포종 종양에 많이 나타나는 ALK 유전자 변이를 표적으로 하는 ALK 억제제, 암세포의 분화와 사멸을 유도하는 이소트레티노인 등의 약물을 이용한 레티노이드 요법이 있습니다.

표적치료와 더불어 면역치료도 신경아세포종 치료의 유망한 수단으로 떠오르고 있습니다. 이 접근법은 신체의 면역 체계를 활용하여 암과 싸우는 것으로, 면역 체크포인트 억제제나 CAR-T 세포 요법과 같은 약물이 임상시험에서 유망한 결과를 보여주고 있습니다. 면역관문억제제는 면역체계가 암세포를 공격하는 것을 방해하는 단백질을 차단하는 방식으로 작용하며, CAR-T 세포 치료는 환자의 T세포가 암세포를 인식하고 죽일 수 있도록 유전자 조작을 통해 암세포를 죽이는 방식입니다. 이러한 치료법은 선택이 제한적이고 일반적으로 예후가 좋지 않은 고위험군 또는 재발성 신경아세포종 환자에게 특히 유용합니다. 또한, 최근 유전체학 및 맞춤의료의 발전으로 신경아세포종 종양의 유전적 변화를 보다 정확하게 파악할 수 있게 되어 개별 환자의 특정 분자 프로파일에 맞는 약물의 개발이 촉진되고 있습니다.

신경아세포종 치료제 시장의 성장은 신경아세포종 발생률 증가, 인식 개선 및 조기 진단, 혁신적인 약물 파이프라인의 확대 등 여러 요인에 기인합니다. 차세대 염기서열 분석 및 첨단 영상 진단 기술과 같은 진단 기술의 발전으로 조기 발견율이 크게 향상되어 보다 적시에 효과적인 개입이 가능해졌습니다. 또한, 제약회사와 학술기관의 연구개발에 대한 막대한 투자로 인해 신약의 발견과 승인이 가속화되고 있습니다. 또한, 맞춤형 의료에 대한 관심이 높아진 것도 이 시장의 성장 동력이 되고 있습니다. 맞춤의료는 환자 개개인의 암에 대한 유전자 구성에 맞춰 치료법을 조정함으로써 치료 효과의 향상과 부작용 감소를 약속하는 것입니다. 또한, 신경아세포종과 같은 희귀질환에 대한 치료제 개발을 촉진하기 위해 희귀의약품 지정, 신속한 심사 절차 등 인센티브를 제공하는 규제기관도 늘고 있습니다. 마지막으로, 환자 옹호 단체와 비영리 단체는 연구 자금을 지원하고 대중의 인식을 높이는 데 중요한 역할을 하고 있으며, 이는 신경아세포종에 대한 첨단 치료법에 대한 수요를 더욱 촉진하고 있습니다.

조사 대상 기업 예시(주목받는 86개 기업)

  • APEIRON Biologics AG
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences Inc.
  • Clarity Pharmaceuticals
  • Creative Biolabs
  • Eli Lilly And Company
  • Eugia US LLC
  • Macrogenics Inc.
  • Provectus Biopharmaceuticals, Inc.
  • Recordati Group
  • Sartorius AG
  • United Therapeutics Corporation
  • USWM, LLC.
  • Y-mabs Therapeutics Inc.;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 24.09.04

Global Neuroblastoma Drugs Market to Reach US$1.1 Billion by 2030

The global market for Neuroblastoma Drugs estimated at US$802.7 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$616.8 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.0 Million While China is Forecast to Grow at 5.0% CAGR

The Neuroblastoma Drugs market in the U.S. is estimated at US$211.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$183.1 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Neuroblastoma Drugs Market - Key Trends and Drivers Summarized

Neuroblastoma is a type of cancer that primarily affects young children and arises from immature nerve cells found in several areas of the body. The treatment landscape for neuroblastoma has evolved significantly over the years, with advancements in drug development playing a pivotal role in improving outcomes. Traditional treatment methods have included surgery, radiation therapy, and chemotherapy, but these approaches often come with significant side effects and varying degrees of success. Recently, there has been a shift towards more targeted therapies, which aim to directly interfere with the cancer cells' ability to grow and proliferate. One such targeted therapy is the use of monoclonal antibodies, like dinutuximab, which binds to the GD2 ganglioside found on neuroblastoma cells, thereby marking them for destruction by the immune system. Other notable drugs include ALK inhibitors, which target mutations in the ALK gene often found in neuroblastoma tumors, and retinoid therapy with drugs like isotretinoin, which induces cancer cell differentiation and death.

In addition to targeted therapies, immunotherapy has emerged as a promising avenue for treating neuroblastoma. This approach leverages the body's immune system to fight cancer, with agents such as immune checkpoint inhibitors and CAR-T cell therapy showing encouraging results in clinical trials. Immune checkpoint inhibitors work by blocking proteins that prevent the immune system from attacking cancer cells, while CAR-T cell therapy involves genetically modifying a patient's T-cells to recognize and kill cancer cells. These therapies are particularly valuable for patients with high-risk or relapsed neuroblastoma, who have limited options and typically poor prognoses. Moreover, recent advancements in genomics and personalized medicine are enabling more precise identification of the genetic alterations in neuroblastoma tumors, facilitating the development of drugs tailored to the specific molecular profiles of individual patients.

The growth in the neuroblastoma drugs market is driven by several factors, including the increasing incidence of neuroblastoma, heightened awareness and early diagnosis, and the expanding pipeline of innovative drugs. Advances in diagnostic technologies, such as next-generation sequencing and advanced imaging techniques, have significantly improved early detection rates, allowing for more timely and effective interventions. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and approval of new therapies. The market is also benefiting from a growing emphasis on personalized medicine, which promises to enhance treatment efficacy and reduce adverse effects by tailoring therapies to the unique genetic makeup of each patient's cancer. Additionally, regulatory agencies are increasingly offering incentives such as orphan drug designations and expedited review processes to encourage the development of treatments for rare diseases like neuroblastoma. Lastly, patient advocacy groups and non-profit organizations are playing a critical role in funding research and raising public awareness, further driving the demand for advanced neuroblastoma therapies.

Select Competitors (Total 86 Featured) -

  • APEIRON Biologics AG
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • Cellectar Biosciences Inc.
  • Clarity Pharmaceuticals
  • Creative Biolabs
  • Eli Lilly And Company
  • Eugia US LLC
  • Macrogenics Inc.
  • Provectus Biopharmaceuticals, Inc.
  • Recordati Group
  • Sartorius AG
  • United Therapeutics Corporation
  • USWM, LLC.
  • Y-mabs Therapeutics Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Neuroblastoma Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Pediatric Cancer Incidence Spurs Growth in Neuroblastoma Drug Development
    • Innovative Treatment Approaches Propel Growth in Neuroblastoma Drugs Market
    • Advancements in Immunotherapy Accelerate Demand for Neuroblastoma Treatments
    • Emerging Gene Therapy Technologies Strengthen Business Case for Novel Neuroblastoma Drugs
    • Precision Medicine Expands Addressable Market Opportunity for Targeted Neuroblastoma Therapies
    • Growing Awareness and Early Diagnosis Generate Demand for Effective Neuroblastoma Medications
    • Advancements in Biomarker Research Enhance the Business Case for Personalized Neuroblastoma Therapies
    • Rising Healthcare Expenditure Generates Opportunities in Neuroblastoma Drug Market
    • Focus on Quality of Life Improvements Spurs Demand for New Neuroblastoma Drug Therapies
    • Evolving Landscape of Combination Therapies Expands Addressable Market for Neuroblastoma Drugs
    • Technological Innovations in Drug Formulation Propel Neuroblastoma Treatment Advancements
    • Growing Interest in Orphan Drug Designations Generates Demand for Neuroblastoma Research
    • Advancements in Pharmacogenomics Strengthen Business Case for Tailored Neuroblastoma Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuroblastoma Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuroblastoma Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neuroblastoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • JAPAN
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CHINA
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • EUROPE
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Neuroblastoma Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Neuroblastoma Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • FRANCE
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • GERMANY
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Italy 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: UK 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Neuroblastoma Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for Neuroblastoma Drugs by Therapy - Immunotherapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of World 16-Year Perspective for Neuroblastoma Drugs by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Neuroblastoma Drugs by Route Of Administration - Injectables Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Neuroblastoma Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Injectables Administration and Oral Administration for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Neuroblastoma Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Neuroblastoma Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제